Jun Ma: h-index, Total Citations, and Citation Map
Jun Ma's h-index is 88 (288 i10-index, 31,529+ total citations across 293+ publications) according to Google Scholar as of July 2026. Jun Ma is affiliated with 中山大学肿瘤防治中心.
Jun Ma is a researcher affiliated with 中山大学肿瘤防治中心, specializing in 肿瘤学. Their work has been cited 31,529 times. This profile visualizes their global influence, highlighting strong citation networks in China.
Jun Ma's Citation Metrics
Bibliometric impact based on 293 indexed publications. Of these, 19 are original research articles — the rest are literature highlights, conference abstracts or theses.
- H-Index
- 88
- i10-Index
- 288
- Total Citations
- 31,529
- Citing Countries
- 58
As of July 2026.
Jun Ma has an h-index of 88 and 31,529 total citations across 293 publications, with research cited by institutions in 58 countries.
Download Exports (PNG, CSV, Poster)
Free Viewing Jun Ma's citation map is always free. Pay once to download poster, PNG, and CSV files for offline use or your visa packet.
Global Impact Map
Visualizing the geographic distribution of institutions that have cited your work.
Starting…
Pins will appear here as institutions are resolved — no need to refresh.
Nasopharyngeal carcinoma
20193,517
Top Citing Countries
Top Citing Institutions
Visa Evidence Package
Views and exports tuned for EB-1A, O-1A, and EB-2 NIW petitions. Sustained acclaim, geographic reach, and independent-citation filtering are the strongest evidence categories immigration adjudicators look for.
Significant Contributions
Auto-detected research lines — a seminal paper and the follow-up work building on it. Review and edit before using in a petition. Each Free PDF opens in a new tab — EB-1A organises this into the structure USCIS applies to Criterion 5 of 8 CFR § 204.5(h)(3)(v); EB-1B re-frames it under § 204.5(i)(3) (outstanding researcher); NIW presents it under prong 2 of Matter of Dhanasar.
1093 citing papers could not be classified (no author data) — excluded from the percentages above.
The researcher established foundational evidence comparing radiotherapy modalities for nasopharyngeal carcinoma, subsequently advancing systemic treatment standards and comprehensive clinical guidelines through highly cited, independent scholarly work.
The researcher established evidence-based standards for concurrent chemoradiotherapy in nasopharyngeal carcinoma through a pivotal phase 3 trial, subsequently shaping major international clinical guidelines.
The researcher established a prognostic microRNA signature for nasopharyngeal carcinoma, subsequently exploring molecular mechanisms and treatment efficacy to advance clinical management.
Citation trend (last 10 years)Click to expand
Citation Trend (Last 10 Years)
Related Guides
Learn how to use citation maps for your research and visa applications.
About Jun Ma's research
Jun Ma is a researcher in 肿瘤学 at 中山大学肿瘤防治中心. Their work has been cited 31,529 times across 293 publications (h-index 88), according to Google Scholar.
Their most-cited work, “Nasopharyngeal carcinoma” (2019), has accumulated 3,517 citations. Other influential works include “Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre …” (2016) with 1,026 citations and “Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma” (2019) with 956 citations.
Citations of Jun Ma's research come primarily from China, United States and Hong Kong, reflecting international research impact across 5+ countries. The interactive citation map above shows the full geographic distribution of the institutions citing this work.
